Text size :

Carrafiello (UniMi): “Interventional radiology fourth pillar in cancer treatment”

ADNKRONOS

November 6, 2026

Rome, 6 Nov. (Adnkronos Health) – “Interventional radiology plays a fundamental role today, and all interventional radiologists are now part of multidisciplinary teams to define the most correct approach to the patient and the pathology itself. The radiologist is no longer just a diagnostician; they have moved beyond the purely diagnostic phase, also approaching therapy thanks to interventional radiology, which now represents the fourth pillar in cancer treatment alongside surgery, radiotherapy, and chemotherapy.” This was stated by Gianpaolo Carrafiello, full professor of Diagnostic Imaging at the University of Milan and director of the Services Area Department at Policlinico di Milano, participating in the second day of the 52nd Sirm Congress – Italian Society of Medical and Interventional Radiology, currently underway in the Lombard capital.

“There are different types of treatment, such as percutaneous ablation, where methods that use heat or cold can be employed, such as microwaves, radiofrequency, or cryoablation,” explains the expert. “There are also non-thermal methods, such as irreversible electroporation, which causes an alteration at the cellular membrane level: this promotes the penetration of the drug into tumor cells or even destroys them. This type of treatment can work synergistically with chemotherapy because it determines a change in the patient’s immunological asset, expressing more antigens and thus achieving greater efficacy from the chemotherapeutic drug used subsequently.”

Following these treatments, “over the years, the most studied and most treated oncological pathology has been hepatocellular carcinoma, the primary liver tumor,” illustrates Carrafiello. “Today, however, liver metastases also derive significant benefit, so much so that the latest studies have shown that ablative treatments offer results comparable to surgery itself, with advantages for the patient as they reduce hospital stay times. The patient certainly has better tolerability towards this type of therapy. In other areas, such as renal cancer, there is a clinical efficacy of around 94-95%. Added to this is the great advantage that these are nephron-sparing methods: they do not destroy the kidney but only target the tumor lesion. As for other therapies, there are endovascular types, useful in more widespread pathologies when an entire organ needs to be attacked with local chemotherapeutic treatments. All this reduces systemic effects in favor of greater success of local treatment. On the other hand, today we still have some limitations in the size of tumors we can treat,” the expert points out. “We can safely intervene on lesions up to 3-3.5 centimeters, after which ablation in a single session or with a single placement may not be entirely effective. However, the goal is often not just to completely destroy the tumor, but to change the immunological setup so that the patient can respond better to chemotherapy,” he concludes.

Jiji Press

Related

Page TOP